Overall verdict
Sell
1.5/10
1-year performance
-7.87%
Score breakdown
Down 7.9% over 1 year, 7% of the 52-week range.
AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration ; AP505 that is in phase I clinical trials for treating solid tumors ; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas ;
AP402, which is in the pre-clinical research phase for breast cancer patients ; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. The company was founded in 2013 and is based in Taipei, Taiwan.
Sector
Health Care
Industry
Biotechnology
Primary listing
Tpex
Taiwan
CEO
Jeng-Horng Her
Founded
2013
Employees
43
Revenue / employee
0 TWD
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
236.00 TWD
52-week low
86.10 TWD
1-year performance
-7.87%
Declining
Year-to-date performance
-46.00%
Declining
Drawdown
-58.81%
Major drawdown
Position in the 52-week range
7% of range
ROIC -22.4%, ROE -23.0%.
Net margin
—
Sector -213.59%|S&P 13.35%
Gross margin
—
Return on equity (ROE)
-23.01%
Negative
Sector -55.92%|S&P 16.98%
Return on invested capital (ROIC)
-22.42%
Negative
Free cash flow margin (FCF)
—
-100.0% a year over 5.
Revenue (trailing 12 months)
0 TWD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
9.5Md TWD
Financial strength
4.7/10Cash covers 3887.5% of the debt, net debt/EBITDA 4.4x.
Net debt / EBITDA
4.4x
Stretched
Gearing (net debt / equity)
-90.91%
Net cash
Cash
1.9Md TWD
Cash / market cap
20.52%
Very solid
Cash / total debt
3887.53%
Net cash
Interest coverage
-361.4x
Stretched
Net debt
-1.9Md TWD
Equity
2.1Md TWD
Closed daily candles, 2 years
Last close on November 20, 2026: 97.20 TWD
- MM20120.38
- MM50122.03
- MM200138.26
- RSI 1433.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.78%
200-day average slope, 3 months
-5.46%
50-day average slope, 1 month
+6.68%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.95 % per day
Volatility change
+19.01%
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.4x | -3.9 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | 0.3x | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
